Biotech Values

[DewDiligence]

GSK/INVA—FDA approves Trelegy Ellipta—first triple-MoA product for COPD:

http://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-approved-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-appropriate-patients-with-copd-in-the-us/

Trelegy Ellipta contains an ICS, a LAMA, and a LABA.

INVA is the former THRX (#msg-119698593).